Weekly Market Update: Quantitative Easing, Redux
The European Central Bank launched a quantitative easing program of its very own this week, pledging to expand its balance sheet by at least €1.1 trillion via purchases of Eurozone sovereign bonds. The ECB move had been extremely well telegraphed to markets but European equities rocked higher and the euro tanked on the news nevertheless (the EuroStoxx50 gained 5.6% on the week, EUR/USD plummeted to 12-year lows). The Shanghai and Hong Kong indices saw robust gains as the mixed 2014 Chinese GDP report gave investors hope that more PBoC easing might be right around the corner. More current data only highlighted China's slowdown: the January flash HSBC PMI reading suggested manufacturing could contract for a second consecutive month. In the US, equities made back most of their losses from last week and the 10-year UST yield consolidated below 1.85% while many European government bond rates hit new lifetime lows after the QE announcement. Markets also digested an influx of corporate earnings reports and 2015 outlooks. For the week, the DJIA added 0.9%, the S&P500 gained 1.6% and the Nasdaq rose 2.7%.
The ECB will purchase €60 billion of sovereign debt from Eurozone member states every month until at least September 2016. The program may very well go on longer, until, as Draghi said, "we see a sustained adjustment in the path of inflation." In a concession to German QE skeptics, both the ECB and member national central banks will buy bonds, sharing the risk of default. The Germans were hardly appreciative: Bundesbank President Weidmann rejected the new QE program and said it would be very challenging to hike rates when they were needed. The euro plunged after the announcement, with EUR/USD testing the lower end of 1.11, for 12-year lows. Some analysts suggested EUR/USD could go to parity soon. Yields on peripheral Eurozone debt plunged to all-time lows, while the 10-year bund yield dropped to a record low of 0.353%.
Less than a week after the Swiss National Bank yanked away its euro peg, markets were surprised by another central bank as the Bank of Canada unexpectedly cut its key rate just a day ahead of the ECB QE announcement. The Bank of Canada cut rates 25 basis points to 0.75% justifying the move on grounds of falling oil prices and slowing reduction of excess capacity. Less surprisingly, the Danish central bank cut its deposit rate to -0.20% and its lending rate to 0.05% to offset the ECB action. Meanwhile the minutes of the last Bank of England meeting revealed a big shift on the MPC: two former hawkish members changed their policy stances, saying the bank should hold off on rate hikes due to prolonged low inflation.
The IMF cut its 2015 global GDP forecast to 3.5% from 3.8% and reduced its 2016 global outlook to 3.7% from 4.0%. China and Japan were cut 0.3 pts and 0.2 pts to 6.8% and 0.6%, respectively for 2015, while the US was the only major economy to have its outlook raised. The IMF remarked that the dimming outlook worldwide underscores need for stronger policy action to boost growth, and that even the positive aspect of lower oil prices is offset by the broad slowdown.
Swiss officials were out in force defending their decision to drop the EUR/CHF floor. SNB Chief Jordan said the cap was no longer justified because the Swiss economy was improving and was never meant to be permanent anyway. Jordan acknowledged that the economic situation in Switzerland was more difficult after the decision while pleading that SNB monetary policy couldn't make everybody happy. Swiss Finance Minister Widmer-Schlumpf estimated that EUR/CHF at 1.10 was a reasonable level for the nation's exporters. EUR/CHF approached last week's low of 0.9749, prompting chatter the SNB would have to cut rates again.
The decline in crude prices slowed this week, with both WTI and Brent hovering around the mid-to-high-$40s range throughout the week. At Davos, OPEC Secretary General El-Badri asserted that oil prices would stay around $45-50 as global economic weakness kept prices low. Back at the ranch in Saudi Arabia, King Abdullah finally passed away after several weeks of rumors he had already died. Salman bin Abdulaziz Al Saud, the 79-year old brother of the king and a former Minister of Defense, was installed as the new monarch. Reports suggest he is in poor health and possibly has dementia, with the complicated royal family riven by factional disputes. Crude saw a brief rally on the confirmation of Abdullah's death, but returned to trend as Salman pledged to continue all of his predecessor's policies.
In earnings, oil services names Halliburton and Baker Hughes both topped market expectations in fourth-quarter reports, with solid earnings and very good revenue growth. Airlines Southwest and United Continental saw solid gains after both firms comfortably beat earnings expectations. US-traded Industrials Honeywell and General Electric gained after solid quarterly results. Shares of German software giant SAP dumped after the company cut its profit outlook through its 2017 fiscal year, while IBM sank after disclosing yet another quarter of y/y revenue contraction and some less than stellar FY15 guidance. American Express unveiled a plan to restructure, cutting 6% of its workforce. UPS skidded after cutting its FY14 outlook on greater-than-expected fourth-quarter expenses. McDonald's fourth quarter results were severely undercooked: the firm missed on the top- and bottom lines, while comps remained negative in all major regions. Netflix soared on good gains in subscribers, especially in international markets.
After a very mixed Q4 in China, there had been fears that China's 2014 GDP would miss both official and market expectations. The figure came in at 7.4%, beating the 7.3% consensus outlook but below Beijing's 7.5% target, the first time the official goal has been missed since 1998 and the lowest rate of growth in 24 years. The consumption component of GDP rose to 51.2% from 48.2% in 2013, reflecting continued rebalancing of the economy. December industrial production topped estimates to reach a 3-month high, as power generation beat the low power consumption figure estimated by the National Energy Administration last week. Later in the week, the PBoC injected liquidity into money markets via reverse repos for the first time in nearly a year in anticipation of Lunar New Year holiday cash demand. HSBC flash manufacturing PMI also beat expectations and improved to 49.8 despite remaining in contraction territory for the 2nd straight month. After a perilous 7.7% plunge on Monday due to regulatory scrutiny of margin securities at trading firms, the Shanghai Composite regained its footing, testing a 5-year high above 3,400 on Friday.
As anticipated, the Bank of Japan maintained its key policy tool to expand the monetary base by ¥80 trillion a year, while also extending its low-rate funding scheme by a year and boosting provision to each institution from ¥1T to ¥2T. The BoJ also kept its overall economic assessment, but raised its view on industrial output to state that it has bottomed. Accompanying the decision, the BOJ released its updated forecasts of growth and inflation, lowering the 2015 GDP target to -0.5% from +0.5% but raising its forecasts for the next two years. The CPI outlook was particularly less rosy for FY15/16, as Governor Kuroda lowered the target to 1.0% from 1.7% and effectively acknowledged that Japan would miss its 2-year time frame to return to 2% inflation. Speaking in Davos on Friday, Kuroda maintained there's still plenty of scope to adjust policy if needed.
The stock market capped a solid week with a shaky Friday session. The S&P 500 lost 0.6%, but still gained 1.6% for the week while the Nasdaq Composite (+0.2%) was able to register its fifth consecutive advance.
Equity indices began the day amid selling activity that started in the futures market after UPS (UPS 102.93, -11.32) issued disappointing guidance due to weakness in the U.S. domestic segment. The logistics company plunged below its 100-day moving average to end lower by 9.9%. The big loss weighed on the Dow Jones Transportation Average, which lost 1.8% and pressured the industrial sector (-0.8%).
The S&P 500 followed the opening slip with an eight-point rally off its morning low after European Central Bank member Benoit Coeure said the bank will need to do more if the quantitative easing program that was announced yesterday does not produce the desired outcome.
Despite the morning charge off session lows, the index never made it into the green and slid to a new low during the final hour of the trading day. The industrial sector kept the pressure on the market throughout the day while other influential groups like financials (-1.0%) and consumer staples (-1.1%) kept the S&P 500 from moving into the green.
The financial sector struggled despite better than expected reports from a slew of regional banks. The economically-sensitive group widened its January decline to 3.5% in response to a combination of slow global growth and sinking yields around the world.
Elsewhere, the consumer staples sector hovered near the bottom of the leaderboard after Kimberly-Clark (KMB 111.65, -7.33) reported below-consensus results and issued cautious guidance, which failed to justify the company's rich valuation.
Also of note, the energy space (-0.9%) spent the bulk of the day in-line with the market, but finished among the laggards as crude oil remained weak. The energy component showed overnight volatility after it was reported Saudi Arabia's King Abdullah has died.
WTI crude was able to make an intraday appearance in the green, but ended lower by 1.8% at $45.56/bbl. Once again, dollar strength was a headwind with the Dollar Index (94.92, +0.86) spiking 0.9%.
On the upside, utilities (+0.3%) and technology (+0.2%) were the only two advancers. The utilities sector solidified its spot atop the January leaderboard (+4.2%) while technology received support from large cap names. Chipmakers were not as fortunate with the PHLX Semiconductor Index ending lower by 0.3%. The high-beta group finished ahead of the S&P 500, but behind the tech sector after KLA-Tencor (KLAC 65.42, -5.53) issued disappointing guidance that overshadowed better than expected results.
Outside of technology, the consumer discretionary sector (-0.2%) was the only other group able to finish near its flat line. Starbucks (SBUX 88.12, +5.38) soared 6.5% even though its in-line report featured below-consensus guidance for the second quarter while McDonald's (MCD 89.56, -1.33) lost 1.5% after missing estimates and priming the market for negative comparable store sales in January.
Treasuries ended near their highs with the 10-yr yield sliding six basis points to 1.80%. Meanwhile, the long bond spiked to pressure its yield to the lowest close on record (2.39%).
Participation was a bit below average with roughly 765 million shares changing hands at the NYSE floor.
Economic data was limited to Existing Home Sales and Leading Indicators:There is no economic data on Monday's schedule, but investors will be responding to the results of the Greek election and its implications for financial markets.
- Existing home sales increased 2.4% in December to 5.04 million SAAR from a downwardly revised 4.92 million SAAR (from 4.93 million SAAR) in November while the consensus expected an increase to 5.10 million SAAR.
- Improvements in the labor market, gains in stock prices, and a general decline in mortgage rates were not enough to boost housing demand in 2014. For the year, 4.93 million homes were sold, which was down 3.1% from the 5.09 million homes sold in 2013
- The Conference Board's Leading Economic Index increased 0.5% in December (consensus 0.5%) after increasing a downwardly revised 0.4% (from 0.6%) in November
- Nasdaq Composite +0.5% YTD
- S&P 500 -0.3% YTD
- Dow Jones Industrial Average -0.8% YTD
- Russell 2000 -1.1% YTD
2015-01-23 20:58:41.390 GMT
By Cynthia Koons, David Wainer and Manuel Baigorri
(Bloomberg) -- In pursuit of growth, Pfizer Inc. is casting
a wide net that included an approach to Teva Pharmaceutical
Industries Ltd. late last year, people familiar with the matter
said.
The Israeli drugmaker immediately rejected Pfizer’s
overtures, so the contours of a transaction never took shape,
said the people, who asked not to be identified because the
matter was private.
The approach by Pfizer underscores how broad the company’s
search for options has become after failing to strike an almost
$120 billion deal with U.K. drugmaker AstraZeneca Plc last year.
In October, Chief Executive Officer Ian Read said he felt
pressure to do a deal to bulk up the innovative part of the
business. The loss of key patents for blockbuster drugs has left
Pfizer with some revenue holes to fill. “Certainly I feel a
sense of urgency on utilizing our balance sheet and our capital
to do deals that are incremental, add incremental value and
certainly add revenue growth in the innovative space,” Read
said on a conference call with analysts in October. “We are
aggressively looking at all alternatives.”
Press representatives for Teva and Pfizer declined to
comment. Teva is valued at about $50 billion, based on today’s
trading.
While a full-blown takeover of Teva would’ve faced
significant hurdles, Teva’s $9.2 billion-a-year generic drugs
business offers Pfizer a way to beef up its portfolio of off-
patent medicine and give it infrastructure to eventually spin
off into a separate company, three of the people said.
Those products, drugs like Pfizer’s Lipitor that have lost
patent protection but are still well-known brands, require
little additional investment and can generate substantial cash.
Teva makes generic versions of blood pressure drug Diovan, blood
thinner Plavix and antibiotic amoxicillin.
German Partner
The AstraZeneca deal was attractive to Pfizer in part
because of the U.K. company’s oncology pipeline. The proposed
deal would also have let New York-based Pfizer relocate its
legal address overseas, allowing it to lower its U.S. tax bills.
Months after Pfizer dropped its pursuit, the U.S. Treasury
Department imposed rules to limit the tax benefits of so-called
inversion deals. Pfizer’s management hasn’t ruled out doing an
inversion in the wake of those changes.
In November, Pfizer announced a partnership with Germany’s
Merck KGaA, boosting its foothold in oncology by giving it
rights to an experimental drug that’s part of an emerging class
of cancer therapies.
Pfizer is still looking for something to buy after the
failed attempt to acquire AstraZeneca, said people familiar with
the matter. The company has been exploring many ideas, including
talks with Actavis Plc before the company agreed to buy Allergan
Inc., one of the people said.
‘Ample Resources’
For its part, Teva is also looking for deals. The company’s
cash balance provides “ample resources” to look for
acquisitions, Chief Executive Officer Erez Vigodman said in an
investor presentation this month.
Pfizer, the largest U.S. drugmaker, has a legacy of being
an M&A powerhouse. In 2000, New York-based Pfizer paid $116
billion for Warner-Lambert Co.; in 2003 it spent $60 billion for
Pharmacia Corp.; and in 2009 it paid more than $60 billion for
Wyeth LLC -- acquisitions that gave Pfizer blockbuster products
like Lipitor and Prevnar.
Pfizer will probably continue striking deals, in part
because executives have the money to spend, said Damien Conover,
a Chicago-based analyst from Morningstar Inc. The company also
faces pressure to do something because its profit is expanding
relatively slowly, he said.
‘A Lot Left’
“While they do a lot of share repurchases, there’s still a
lot left for them to make acquisitions,” Conover said.
“They’re really motivated to get some growth through some
external collaborations.”
Pfizer should exercise caution in doing deals, said David
Heupel, senior health-care analyst at Thrivent Financial, which
holds Pfizer shares. “I think operationally there are a lot of
positives that are overlooked,” he said. “I’d rather them
execute on that kind of strategy than go out and really stretch
to do a big deal.”
For Related News and Information:
Top Health News: TOP HEA <GO>
--With assistance from Tara Lachapelle and David Welch in New
York.
To contact the reporters on this story:
Cynthia Koons in New York at +1-212-617-5253 or
ckoons@bloomberg.net;
David Wainer in Tel Aviv at +972-3-542-7110 or
dwainer3@bloomberg.net;
Manuel Baigorri in London at +44-20-3525-4457 or
mbaigorri@bloomberg.net
To contact the editors responsible for this story:
Crayton Harrison at +1-212-617-6145 or
tharrison5@bloomberg.net;
Mohammed Hadi at +1-212-617-2914 or
mhadi1@bloomberg.net;
Chitra Somayaji at +44-20-3525-9717 or
csomayaji@bloomberg.net
Drew Armstrong
Subject: Fwd:>>> VLO US : *INCREASES DIVIDEND 45% TO $0.40 FROM $0.275
*INCREASES DIVIDEND 45% TO $0.40 FROM $0.275- CEO: "This significant increase in our regular cash dividend shows our commitment to returning cash to stockholders,”- effective with the quarterly dividend the Board has declared to be payable on March 3, 2015 to holders of record at the close of business on February 11, 2015.- Note: Yield implied approx 3.2%
2015-01-23 19:52:11.759 GMT
--JOSHUA FINEMAN
-0- Jan/23/2015 19:52 GMT
2015-01-23 18:46:52.796 GMT
By Corinne Gretler
(Bloomberg) -- “We have a margin that allows us to
continue to invest in the business,” Nestle CEO Paul Bulcke
said at a panel at World Economic Forum in Davos.
* Bulcke declined to comment on Nespresso’s profit margins
* “If we cannot be competitive in a product, we shouldn’t be
in there": Bulcke
* Nespresso pays 30%-40% above market price for coffee as it
uses narrow selection of beans: Bulcke
Link to Company News:{NESN VX <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the editor responsible for this story:
Corinne Gretler at +41-44-224-4100 or
cgretler1@bloomberg.net